Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The main goal of this first in human (FIH) study is to learn about the safety and dosing of
GS-9911 when given alone or in combination with an anti-programmed cell death protein 1
(PD-1) monoclonal antibody in participants with advanced solid tumors.
The primary objectives of this study are to:
- Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an
anti-PD-1 monoclonal antibody in participants with advanced solid tumors
- Identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the
recommended dose for expansion (RDE) of GS-9911 as monotherapy and in combination with
an anti-PD-1 monoclonal antibody in participants with advanced solid tumors